admin
Pharma and nutraceutical brands face a strategic choice as they grow: keep outsourcing production to third party manufacturers or invest in their own facility. There is no universal answer. The right model depends on volumes, margins, markets, capital and the level of control you need. A structured comparison makes the decision much clearer.
Understanding the Models
In third party manufacturing, a licensed manufacturer produces products that you market under your brand. In a loan licence arrangement, you hold a licence to manufacture at another company’s facility and take greater responsibility for the product. With an own facility, you control everything from raw material purchase to batch release.
The Case for Third Party Manufacturing
- No large upfront capital investment in land, buildings or equipment
- Faster product launches using existing licensed and certified facilities
- Access to multiple dosage forms through different specialised partners
- Flexibility to scale volumes up or down with demand
- Management focus stays on sales, marketing and brand building
Contract manufacturing is especially attractive for new brands, companies testing new markets and businesses with broad portfolios where no single product justifies dedicated capacity.
The Case for an Own Facility
- Full control over quality, scheduling and costs
- Better margins at high, stable volumes
- Stronger positioning for regulated market registrations and partnerships
- Protection of proprietary formulations and processes
- Asset value for future investment, valuation or acquisition
Side by Side Comparison
| Factor | Third party | Own facility |
|---|---|---|
| Upfront investment | Low | High |
| Time to market | Weeks to months | One to two years or more |
| Cost per unit at scale | Higher | Lower |
| Control over scheduling | Shared with other clients | Full |
| Regulatory responsibility | Shared through quality agreement | Full |
| Flexibility | High | Lower, tied to installed capacity |
Hidden Costs to Consider
Contract manufacturing prices may look higher per unit, but owning a plant brings costs that are easy to underestimate: quality and engineering staff, maintenance, validation, utilities, compliance audits, idle capacity and working capital. Conversely, outsourcing carries hidden risks such as capacity conflicts during peak demand, dependence on a single partner and slower response to quality issues.
Managing Contract Manufacturing Well
- Qualify partners through site audits, not only certificates.
- Sign a detailed quality agreement defining responsibilities.
- Agree clear specifications, testing and release procedures.
- Review batch records and trends regularly.
- Keep a qualified backup manufacturer for critical products.
Questions to Ask Before Deciding
- Are your volumes large and predictable enough to keep a plant busy?
- Do you have the capital and management bandwidth for a multi year project?
- Which markets require site specific registrations or inspections?
- How important is speed to market for your next launches?
- Would owning a facility increase the value of your business?
Many successful companies use a hybrid model: core high volume products in their own plant and specialised or new products with trusted contract partners.
Planning the Transition
If you decide to move from outsourcing to your own facility, plan the transition carefully. Technology transfer, validation batches and regulatory variations for the change of manufacturing site all take time. Keep the contract partner supplying until the new site is approved to avoid stock outs.
What a Good Quality Agreement Covers
The quality agreement is the most important document in a contract manufacturing relationship. It defines who does what, and it is reviewed by inspectors and auditors.
- Responsibilities for sourcing and testing raw and packing materials
- Manufacturing, in process controls and batch record review
- Finished product testing, release and retention samples
- Change control, deviation handling and notification timelines
- Complaints, recalls and pharmacovigilance responsibilities
- Audit rights and frequency
Protecting Your Formulation and Brand
Sign a non disclosure agreement before sharing formulations, and consider splitting critical know how where appropriate. Register trademarks for your brand names and ensure that artwork, cartons and dossiers identify you as the brand owner. Where you fund development, make sure the agreement states that the formulation and related data belong to you.
Evaluating the Numbers
Build a simple five year model comparing both options. Include contract manufacturing prices at expected volumes against the full cost of an owned plant, covering depreciation, finance cost, staffing, utilities, maintenance, compliance and expected capacity utilisation. The break even point often arrives later than promoters expect, which is why many companies extend contract manufacturing longer than originally planned.
Regulatory Considerations for Each Model
For export markets, product registrations name the manufacturing site. If you work with a contract manufacturer, your dossiers and registrations will reference their site, and moving production later requires variations and sometimes new stability data or inspections. When building your own facility, factor in the time needed to transfer registrations to the new site before stopping supply from the contract partner.
Domestic regulations also define responsibilities for brand owners and manufacturers, including labelling, quality accountability and pharmacovigilance. Make sure the chosen model, whether third party, loan licence or own facility, is structured in line with current regulations and that every party understands its obligations.
Whichever model you choose, invest in a strong internal quality function. Even when manufacturing is outsourced, the brand owner is responsible for the products that reach patients and consumers.
Signs It May Be Time to Build
- Contract partners regularly struggle to meet your volumes or timelines
- Your top products have stable, growing demand over several years
- Key customers or markets require direct control of the manufacturing site
- Manufacturing margins paid to partners exceed the projected cost of ownership
If several of these apply, a feasibility study and detailed project report are sensible next steps.
Even then, a phased approach reduces risk. Some companies start with a single dosage form block for their highest volume products, keep contract partners for the rest of the range, and expand the facility as demand grows. This preserves cash, keeps supply secure during the transition and gives the new quality team time to mature before taking on the full portfolio.
Start with contract manufacturing to validate products and markets, then build your own capacity once volumes and margins justify the investment. A hybrid model often gives the best balance of control and flexibility.
Zanax Healthcare supports both paths, offering contract manufacturing through audited partner sites and turnkey project delivery when you are ready to build your own plant.
